Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Inflammatory Bowel Diseases

Free Subscription Articles published in Eur J Gastroenterol Hepatol Retrieve available abstracts of 178 articles: HTML format

Single Articles

July 2021
1. ORFANOUDAKI E, Drygiannakis I, Theodoraki E, Foteinogiannopoulou K, et al
   Real-life utility and diagnostic accuracy of a home-performed fecal calprotectin test to predict endoscopic activity in patients with inflammatory bowel disease under maintenance treatment with adalimumab.
   Eur J Gastroenterol Hepatol. 2021 Jul 19. pii: 00042737-900000000-97178.
   PubMed     Abstract available
   
   
   June 2021
2. RICHTER V, Bermont A, Cohen DL, Broide E, et al
   Effect of inflammatory bowel disease and related medications on COVID-19 incidence, disease severity, and outcome: the Israeli experience.
   Eur J Gastroenterol Hepatol. 2021 Jun 29. pii: 00042737-900000000-97186.
   PubMed     Abstract available
   
   
   
3. ATTAUABI M, Vind I, Pedersen G, Bendtsen F, et al
   Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn's disease - a real-world two-center cohort study.
   Eur J Gastroenterol Hepatol. 2021 Jun 7. pii: 00042737-900000000-97194.
   PubMed     Abstract available
   
   
   May 2021
4. RIZOS ED, Antonogiannaki EM, Chatzidakis A, Kallieri M, et al
   Vedolizumab-induced acute interstitial lung injury in a 39-year-old male with ulcerative colitis.
   Eur J Gastroenterol Hepatol. 2021 May 31. pii: 00042737-900000000-97199.
   PubMed     Abstract available
   
   
   
5. GATOPOULOU A, Christodoulou DK, Katsanos KH, Bakos D, et al
   Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventional, observational study in Gree
   Eur J Gastroenterol Hepatol. 2021 May 21. pii: 00042737-900000000-97217.
   PubMed     Abstract available
   
   
   
6. VOHRA I, Attar B, Haghbin H, Mutneja H, et al
   Incidence and risk factors for 30-day readmission in ulcerative colitis: nationwide analysis in biologic era.
   Eur J Gastroenterol Hepatol. 2021 May 21. pii: 00042737-900000000-97210.
   PubMed     Abstract available
   
   
   
7. ANGELINO G, Cifaldi C, Zangari P, Di Cesare S, et al
   Gastric cancer, inflammatory bowel disease and polyautoimmunity in a 17-year-old boy: CTLA-4 deficiency successfully treated with Abatacept.
   Eur J Gastroenterol Hepatol. 2021 May 21. pii: 00042737-900000000-97208.
   PubMed     Abstract available
   
   
   
8. VAN GENNEP S, Gielen ME, Rietdijk ST, de Boer NKH, et al
   Work productivity loss is determined by fatigue and reduced quality of life in employed inflammatory bowel disease patients: a prospective multicentre cohort study.
   Eur J Gastroenterol Hepatol. 2021 May 3. doi: 10.1097/MEG.0000000000002178.
   PubMed     Abstract available
   
   
   
9. VIGLIO A, Lenti MV, Vanoli A, Di Sabatino A, et al
   Rectal neuroendocrine cell proliferation in a patient with ulcerative colitis treated with adalimumab.
   Eur J Gastroenterol Hepatol. 2021;33:766-768.
   PubMed    
   
   
   April 2021
10. SINGH AK, Jha DK, Jena A, Kumar-M P, et al
    Hyperbaric oxygen therapy in inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2021 Apr 19. doi: 10.1097/MEG.0000000000002164.
    PubMed     Abstract available
    
    
    
11. CORREIA JP, Ponte AI, Silva JC, Gomes AC, et al
    Mesalazine-induced acute pancreatitis: a rare adverse reaction but with important therapeutic implications in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021;33:595.
    PubMed    
    
    
    
12. GONELLA F, Massucco P, Daperno M, Mineccia M, et al
    Ulcerative enteritis. How the extension of ulcerative colitis to small bowel may jeopardize postcolectomy course: a case report and literature review.
    Eur J Gastroenterol Hepatol. 2021;33:589-594.
    PubMed     Abstract available
    
    
    
13. GOMES C, Pinho R, Ponte A, Silva JC, et al
    Patient's perspective on the implementation of measures to contain the SARS-CoV-2 pandemic in a Portuguese Gastroenterology Department.
    Eur J Gastroenterol Hepatol. 2021;33:527-532.
    PubMed     Abstract available
    
    
    March 2021
14. FERNANDES SR, Serrazina J, Rodrigues IC, Bernardo S, et al
    Proactive therapeutic drug monitoring is more effective than conventional management in inducing fecal calprotectin remission in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021 Mar 12. pii: 00042737-900000000-97288.
    PubMed     Abstract available
    
    
    
15. KARIYAWASAM VC, Mourad FH, Mitrev N, Paramsothy S, et al
    Early thiopurine maintenance is associated with reduced proximal disease progression and colectomy rate in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021 Mar 12. pii: 00042737-900000000-97273.
    PubMed     Abstract available
    
    
    
16. SCHARRER S, Kutschera M, Weseslindtner L, Primas C, et al
    Humoral response to COVID-19 infection in immunosuppressed patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021;33:443-447.
    PubMed     Abstract available
    
    
    February 2021
17. KYRIAKOS N, Papaefthymiou A, Giakoumis M, Galanopoulos M, et al
    Prevalence of inflammatory bowel disease in young Greek Army male recruits from 2006 to 2018: a 13-year retrospective study from a tertiary center.
    Eur J Gastroenterol Hepatol. 2021 Feb 26. pii: 00042737-900000000-97290.
    PubMed     Abstract available
    
    
    
18. LOVERO R, Losurdo G, La Fortezza RF, Terracciano F, et al
    Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021;32:201-207.
    PubMed     Abstract available
    
    
    January 2021
19. KOUMAKI D, Machaira A, Katoulis AC, Bitados P, et al
    Mucocutaneous manifestations in patients with inflammatory bowel disease: a decade study from a Greek cohort.
    Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97312.
    PubMed     Abstract available
    
    
    
20. UNAL NG, Oruc N, Tomey O, Omer Ozutemiz A, et al
    Malnutrition and sarcopenia are prevalent among inflammatory bowel disease patients with clinical remission.
    Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97311.
    PubMed     Abstract available
    
    
    
21. MAGRI S, Chessa L, Demurtas M, Cabras F, et al
    Review article: safety of new biologic agents for inflammatory bowel disease in the liver.
    Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97310.
    PubMed     Abstract available
    
    
    
22. STRAATMIJER T, van Gennep S, Duijvestein M, Ponsioen CIJ, et al
    Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2021;Publish Ahead of Print.
    PubMed     Abstract available
    
    
    
23. FIGUEREDO CM, Nunes JGR, Mello-Neto JM, Carvalho AT, et al
    Higher salivary expression of S100A12 in patients with ulcerative colitis and chronic periodontitis.
    Eur J Gastroenterol Hepatol. 2021;33:116-117.
    PubMed    
    
    
    November 2020
24. WEISLINGER L, Guillo L, D'Amico F, Danese S, et al
    Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2020 Nov 30. doi: 10.1097/MEG.0000000000002008.
    PubMed     Abstract available
    
    
    
25. LYUTAKOV I, Lozanov V, Sugareva P, Valkov H, et al
    Serum 7-alfa-hydroxy-4-cholesten-3-one and fibroblast growth factor-19 as biomarkers diagnosing bile acid malabsorption in microscopic colitis and inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2020 Nov 10. doi: 10.1097/MEG.0000000000001925.
    PubMed     Abstract available
    
    
    
26. LYU L, Chen D, Yu M, Yang Y, et al
    The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2020;32:1480-1481.
    PubMed    
    
    
    October 2020
27. GILISSEN LPL, Tajzai R, Romberg M, Pierik M, et al
    The prevalence of nodular regenerative hyperplasia of the liver in long-term thiopurine-treated inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2020 Oct 29. doi: 10.1097/MEG.0000000000001980.
    PubMed     Abstract available
    
    
    
28. ROMEO S, Neri B, Mossa M, Calabrese E, et al
    Finger clubbing in inflammatory bowel disease: association with upper small bowel lesions and need of surgery in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2020 Oct 29. doi: 10.1097/MEG.0000000000001966.
    PubMed     Abstract available
    
    
    
29. KJAERGAARD S, Jensen TSR, Feddersen UR, Bindslev N, et al
    Decreased number of colonic tuft cells in quiescent ulcerative colitis patients.
    Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001959.
    PubMed     Abstract available
    
    
    
30. MOOSVI Z, Duong J, Bechtold ML, Nguyen DL, et al
    Systematic review and meta-analysis: risks of postoperative complications with preoperative use of anti-tumor necrosis factor-alpha biologics in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001944.
    PubMed     Abstract available
    
    
    
31. BHAMBHVANI HP, Zamora A
    Deep learning enabled classification of Mayo endoscopic subscore in patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001952.
    PubMed     Abstract available
    
    
    September 2020
32. LOPETUSO LR, Corbi M, Scaldaferri F, Petito V, et al
    Characterization of mucosal cytokine profile in ulcerative colitis patients under conventional and anti-TNF-a treatment.
    Eur J Gastroenterol Hepatol. 2020 Sep 23. doi: 10.1097/MEG.0000000000001933.
    PubMed     Abstract available
    
    
    
33. VELLOPOULOU K, Stefanou G, Tzanetakos C, Boubouchairopoulou N, et al
    Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece.
    Eur J Gastroenterol Hepatol. 2020 Sep 23. doi: 10.1097/MEG.0000000000001916.
    PubMed     Abstract available
    
    
    
34. MESONERO F, Julia B, Saldana R, Savini C, et al
    Self-medication with oral corticosteroids reported by patients with ulcerative colitis: characteristics, reasons and patients' behaviors.
    Eur J Gastroenterol Hepatol. 2020 Sep 17. doi: 10.1097/MEG.0000000000001931.
    PubMed     Abstract available
    
    
    
35. HORESH N, Mansour A, Simon D, Edden Y, et al
    Postoperative outcomes following inguinal hernia repair in inflammatory bowel disease patients compared to matched controls.
    Eur J Gastroenterol Hepatol. 2020 Sep 17. doi: 10.1097/MEG.0000000000001936.
    PubMed     Abstract available
    
    
    
36. CROOKS B, McLaughlin J, Matsuoka K, Kobayashi T, et al
    The dietary practices and beliefs of people living with inactive ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2020 Sep 17. doi: 10.1097/MEG.0000000000001911.
    PubMed     Abstract available
    
    
    
37. BISCAGLIA G, Piazzolla M, Cocomazzi F, Melchionda G, et al
    Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab.
    Eur J Gastroenterol Hepatol. 2020 Sep 15. doi: 10.1097/MEG.0000000000001919.
    PubMed     Abstract available
    
    
    
38. SBEIT W, Kadah A, Mahamid M, Karayanni H, et al
    Oral manifestations of inflammatory bowel disease: the neglected piece of the puzzle.
    Eur J Gastroenterol Hepatol. 2020 Sep 10. doi: 10.1097/MEG.0000000000001918.
    PubMed     Abstract available
    
    
    
39. MANTAKA A, Tsoukali E, Fragkaki M, Karmiris K, et al
    Is there any role of renin-angiotensin system inhibitors in modulating inflammatory bowel disease outcome?
    Eur J Gastroenterol Hepatol. 2020 Sep 9. doi: 10.1097/MEG.0000000000001912.
    PubMed     Abstract available
    
    
    
40. NIGAM GB, Bhandare AP, Antoniou GA, Limdi JK, et al
    Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy.
    Eur J Gastroenterol Hepatol. 2020 Sep 2. doi: 10.1097/MEG.0000000000001917.
    PubMed     Abstract available
    
    
    August 2020
41. STEFANOVIC S, Detrez I, Compernolle G, Brouwers E, et al
    Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label.
    Eur J Gastroenterol Hepatol. 2020 Aug 14. doi: 10.1097/MEG.0000000000001843.
    PubMed     Abstract available
    
    
    
42. WALJEE AK, Noureldin M, Berinstein JA, Cohen-Mekelburg SA, et al
    Mapping the relationships between inflammatory bowel disease and comorbid diagnoses to identify disease associations.
    Eur J Gastroenterol Hepatol. 2020 Aug 14. doi: 10.1097/MEG.0000000000001869.
    PubMed     Abstract available
    
    
    
43. CASELLAS F, Guinard Vicens D, Garcia-Lopez S, Gonzalez-Lama Y, et al
    Consensus document on the management preferences of patients with ulcerative colitis: points to consider and recommendations.
    Eur J Gastroenterol Hepatol. 2020 Aug 14. doi: 10.1097/MEG.0000000000001885.
    PubMed     Abstract available
    
    
    
44. SRIVASTAVA A, Sathiyasekharan M, Jagadisan B, Bolia R, et al
    Paediatric inflammatory bowel disease in India: a prospective multicentre study.
    Eur J Gastroenterol Hepatol. 2020 Aug 10. doi: 10.1097/MEG.0000000000001859.
    PubMed     Abstract available
    
    
    
45. SANTOS JDM, Pena-Sanchez JN, Fowler SA
    Patients' perspectives on medication for inflammatory bowel disease: a mixed-method systematic review.
    Eur J Gastroenterol Hepatol. 2020 Aug 7. doi: 10.1097/MEG.0000000000001861.
    PubMed     Abstract available
    
    
    June 2020
46. ALAMDARI-PALANGI V, Vahedi F, Shabaninejad Z, Dokeneheifard S, et al
    microRNA in inflammatory bowel disease at a glance.
    Eur J Gastroenterol Hepatol. 2020 Jun 16. doi: 10.1097/MEG.0000000000001815.
    PubMed     Abstract available
    
    
    
47. WIDBOM L, Ekblom K, Karling P, Hultdin J, et al
    Patients developing inflammatory bowel disease have iron deficiency and lower plasma ferritin years before diagnosis: a nested case-control study.
    Eur J Gastroenterol Hepatol. 2020 Jun 11. doi: 10.1097/MEG.0000000000001816.
    PubMed     Abstract available
    
    
    
48. DESAI M, Knight K, Gray JM, Nguyen V, et al
    Low glutamate dehydrogenase levels are associated with colonization in Clostridium difficile PCR-only positive patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2020 Jun 8. doi: 10.1097/MEG.0000000000001762.
    PubMed     Abstract available
    
    
    
49. BASARANOGLU M, Kapsigay M, Kunduz E
    Increased neuroendocrine tumours, but small colorectal cancer incidence in patients with inflammatory bowel disease treated by mesalazine.
    Eur J Gastroenterol Hepatol. 2020;32:763.
    PubMed    
    
    
    May 2020
50. KOURKOULIS P, Michalopoulos G, Katifelis H, Giannopoulou I, et al
    Leucine-rich alpha-2 glycoprotein 1, high mobility group box 1, matrix metalloproteinase 3 and annexin A1 as biomarkers of ulcerative colitis endoscopic and histological activity.
    Eur J Gastroenterol Hepatol. 2020 May 29. doi: 10.1097/MEG.0000000000001783.
    PubMed     Abstract available
    
    
    
51. CHAN W, Kariyawasam VC, Kim S, Pudipeddi AV, et al
    Gastroenterologists' preference and risk perception on the use of immunomodulators and biological therapies in elderly patients with ulcerative colitis: an international survey.
    Eur J Gastroenterol Hepatol. 2020 May 22. doi: 10.1097/MEG.0000000000001768.
    PubMed     Abstract available
    
    
    
52. OZKAN E, Basaranoglu M
    Recurrent 'gloves and socks' distribution with bullous eruptions after adalimumab and infliximab treatment in a patient with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2020;32:666-667.
    PubMed    
    
    
    April 2020
53. LI Q, Zhang T, Ding X, Xiang L, et al
    Enhancing patient adherence to fecal microbiota transplantation maintains the long-term clinical effects in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2020 Apr 10. doi: 10.1097/MEG.0000000000001725.
    PubMed     Abstract available
    
    
    
54. BARDASI G, Romagnoli A, Foschini MP, Mantovani A, et al
    Pyostomatitis vegetans in a pediatric patient with ulcerative colitis: case report of a rare pediatric inflammatory bowel disease extraintestinal manifestation and review of the literature.
    Eur J Gastroenterol Hepatol. 2020 Apr 10. doi: 10.1097/MEG.0000000000001723.
    PubMed     Abstract available
    
    
    
55. BERTANI L, Mumolo MG, Tapete G, Albano E, et al
    Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment.
    Eur J Gastroenterol Hepatol. 2020 Apr 8. doi: 10.1097/MEG.0000000000001731.
    PubMed     Abstract available
    
    
    
56. HANAEI S, Sanati G, Sadr M, Salmanroghani R, et al
    DNA methylation of SOCS3 in intestinal biopsy and peripheral blood samples of Iranian patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2020;32:540-541.
    PubMed    
    
    
    
57. GUNEY M, Basaranoglu M
    A patient with Crohn's disease during remission by biological agent treatment developed active pulmonary tuberculosis and determining the eating habits.
    Eur J Gastroenterol Hepatol. 2020;32:541-542.
    PubMed    
    
    
    March 2020
58. LI X, Sun L, Chen L, Xu Y, et al
    Upregulation of microRNA-219-5p relieves ulcerative colitis through balancing the differentiation of Treg/Th17 cells.
    Eur J Gastroenterol Hepatol. 2020 Mar 13. doi: 10.1097/MEG.0000000000001712.
    PubMed     Abstract available
    
    
    February 2020
59. PHILLIPS J, Preskey R, Penfold C, Gordon F, et al
    Liver steatosis is a risk factor for hepatotoxicity in inflammatory bowel disease patients treated with azathioprine.
    Eur J Gastroenterol Hepatol. 2020 Feb 21. doi: 10.1097/MEG.0000000000001683.
    PubMed     Abstract available
    
    
    
60. KARAIVAZOGLOU K, Konstantakis C, Tourkochristou E, Assimakopoulos SF, et al
    Non-alcoholic fatty liver disease in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2020 Feb 8. doi: 10.1097/MEG.0000000000001679.
    PubMed     Abstract available
    
    
    
61. CHARILAOU P
    Walking on thin ice: considering the fragility index in randomized control trials.
    Eur J Gastroenterol Hepatol. 2020;32:139.
    PubMed    
    
    
    
62. EMAN AS, Shaji S
    Is MRI healing the target in treating perianal fistulizing Crohn's disease?
    Eur J Gastroenterol Hepatol. 2020;32:137-138.
    PubMed    
    
    
    January 2020
63. MANTAKA A, Tsoukali E, Fragkaki M, Karmiris K, et al
    The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2020 Jan 8. doi: 10.1097/MEG.0000000000001674.
    PubMed     Abstract available
    
    
    December 2019
64. ALGETHMI W, Baumann C, Alnajjar W, Sroji A, et al
    Environmental exposures and the risk of inflammatory bowel disease: a case-control study from Saudi Arabia.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001619.
    PubMed     Abstract available
    
    
    
65. KUMAR A, Lukin DJ
    Incident heart failure is a predictor of adverse outcomes in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001648.
    PubMed     Abstract available
    
    
    
66. NERI B, Stingone C, Romeo S, Sena G, et al
    Inflammatory bowel disease versus Chlamydia trachomatis infection: a case report and revision of the literature.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001605.
    PubMed     Abstract available
    
    
    
67. SWEENEY L, Moss-Morris R, Czuber-Dochan W, Murrells T, et al
    Developing a better biopsychosocial understanding of pain in inflammatory bowel disease: a cross-sectional study.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001615.
    PubMed     Abstract available
    
    
    
68. SCHOEPFER A, Vavricka SR, Brungger B, Blozik E, et al
    Systematic analysis of therapeutic patterns and healthcare use during 12 months before inflammatory bowel disease-related hospitalization in Switzerland.
    Eur J Gastroenterol Hepatol. 2019 Dec 9. doi: 10.1097/MEG.0000000000001616.
    PubMed     Abstract available
    
    
    November 2019
69. KAWAKAMI A, Choong LM, Tanaka M, Kunisaki R, et al
    Validation of the English version of the difficulty of life scale for patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2019 Nov 7. doi: 10.1097/MEG.0000000000001595.
    PubMed     Abstract available
    
    
    
70. VIOLA A, Monterubbianesi R, Scalisi G, Furfaro F, et al
    Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study.
    Eur J Gastroenterol Hepatol. 2019;31:1361-1369.
    PubMed     Abstract available
    
    
    
71. NAFTALI T, Bar-Lev Schleider L, Sklerovsky Benjaminov F, Lish I, et al
    Medical cannabis for inflammatory bowel disease: real-life experience of mode of consumption and assessment of side-effects.
    Eur J Gastroenterol Hepatol. 2019;31:1376-1381.
    PubMed     Abstract available
    
    
    October 2019
72. LANGHORST J, Koch AK, Voiss P, Dobos GJ, et al
    Distinct patterns of short-chain fatty acids during flare in patients with ulcerative colitis under treatment with mesalamine or a herbal combination of myrrh, chamomile flowers, and coffee charcoal: secondary analysis of a randomized controlled trial
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001582.
    PubMed     Abstract available
    
    
    
73. KIM S, Park S, Kang Y, Koh H, et al
    Combining faecal calprotectin and sigmoidoscopy can predict mucosal healing in paediatric ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2019 Oct 22. doi: 10.1097/MEG.0000000000001550.
    PubMed     Abstract available
    
    
    
74. QUIROZ-CRUZ S, Posada-Reyes B, Alatorre-Garcia T, Del Real-Calzada CM, et al
    Genetic polymorphisms present in IL10, IL23R, NOD2, and ATG16L1 associated with susceptibility to inflammatory bowel disease in Mexican population.
    Eur J Gastroenterol Hepatol. 2019 Oct 22. doi: 10.1097/MEG.0000000000001540.
    PubMed     Abstract available
    
    
    
75. MOSES J, Lambert-Jenkins K, Momotaz H, Sattar A, et al
    Time to antibody detection and associated factors for presence of anti-drug antibodies in pediatric inflammatory bowel disease patients treated with anti-TNF therapy.
    Eur J Gastroenterol Hepatol. 2019;31:1228-1233.
    PubMed     Abstract available
    
    
    
76. GROCHENIG HP, Waldhor T, Haas T, Wenzl H, et al
    Prevalence and indicators of use of complementary and alternative medicine in Austrian patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2019;31:1211-1219.
    PubMed     Abstract available
    
    
    
77. KOURKOULIS P, Kapizioni C, Michalopoulos G, Andreou NP, et al
    Novel potential biomarkers for the diagnosis and monitoring of patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2019;31:1173-1183.
    PubMed     Abstract available
    
    
    September 2019
78. SCHOENEFUSS F, Hoffmann P
    Serum gamma-globulin and albumin concentrations predict secondary loss of response to anti-TNFalpha in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2019 Sep 16. doi: 10.1097/MEG.0000000000001493.
    PubMed     Abstract available
    
    
    
79. FEUERSTEIN JD, Curran T, Alvares D, Alosilla M, et al
    Surgery for ulcerative colitis in geriatric patients is safe with similar risk to younger patients.
    Eur J Gastroenterol Hepatol. 2019 Sep 11. doi: 10.1097/MEG.0000000000001529.
    PubMed     Abstract available
    
    
    August 2019
80. PETRYSZYN P, Staniak A, Wolosianska A, Ekk-Cierniakowski P, et al
    Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms: meta-analysis.
    Eur J Gastroenterol Hepatol. 2019 Aug 27. doi: 10.1097/MEG.0000000000001509.
    PubMed     Abstract available
    
    
    June 2019
81. SOUSA M, Ladeira I, Ponte A, Fernandes C, et al
    Screening for latent tuberculosis in patients with inflammatory bowel disease under antitumor necrosis factor: data from a Portuguese center.
    Eur J Gastroenterol Hepatol. 2019 Jun 14. doi: 10.1097/MEG.0000000000001469.
    PubMed     Abstract available
    
    
    
82. SHI H, Feng Y, Jiang J, Zhao J, et al
    Correlations between the serum bilirubin level and ulcerative colitis: a case-control study.
    Eur J Gastroenterol Hepatol. 2019 Jun 12. doi: 10.1097/MEG.0000000000001466.
    PubMed     Abstract available
    
    
    
83. WU S, He C, Tang TY, Li YQ, et al
    A review on co-existent Epstein-Barr virus-induced complications in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2019 Jun 12. doi: 10.1097/MEG.0000000000001474.
    PubMed     Abstract available
    
    
    May 2019
84. BRUNA-BARRANCO I, Lue A, Gargallo-Puyuelo CJ, Arroyo MT, et al
    Young age and tobacco use are predictors of lower medication adherence in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2019 May 16. doi: 10.1097/MEG.0000000000001436.
    PubMed     Abstract available
    
    
    
85. LARSEN L, Jess T, Drewes AM, Dige A, et al
    Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment.
    Eur J Gastroenterol Hepatol. 2019 May 14. doi: 10.1097/MEG.0000000000001440.
    PubMed     Abstract available
    
    
    
86. BOKEMEYER B, Luehr D, Helwig U, Maaser C, et al
    Small bowel capsule endoscopy in ulcerative colitis: the capcolitis study: a prospective observational study.
    Eur J Gastroenterol Hepatol. 2019 May 6. doi: 10.1097/MEG.0000000000001410.
    PubMed     Abstract available
    
    
    April 2019
87. VIAZIS N, Pontas C, Karmiris K, Dimas I, et al
    Prevalence of Clostridium difficile infection among hospitalized inflammatory bowel disease patients in Greece.
    Eur J Gastroenterol Hepatol. 2019 Apr 9. doi: 10.1097/MEG.0000000000001414.
    PubMed     Abstract available
    
    
    
88. AKYUZ F, Cavus B, Iliaz R, Soyer OM, et al
    Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?
    Eur J Gastroenterol Hepatol. 2019 Apr 5. doi: 10.1097/MEG.0000000000001403.
    PubMed     Abstract available
    
    
    
89. HALD M, Carlsen K, Nordgaard-Lassen I, Wewer V, et al
    Challenges and obstacles in the transition process through the eyes of the gastroenterologist.
    Eur J Gastroenterol Hepatol. 2019;31:486-493.
    PubMed     Abstract available
    
    
    March 2019
90. DAVIS R, McParland P, Dodd S, Storey D, et al
    Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2019 Mar 6. doi: 10.1097/MEG.0000000000001395.
    PubMed     Abstract available
    
    
    
91. ARIEIRA C, Monteiro S, Xavier S, Dias de Castro F, et al
    Hepatic steatosis and patients with inflammatory bowel disease: when transient elastography makes the difference.
    Eur J Gastroenterol Hepatol. 2019 Mar 4. doi: 10.1097/MEG.0000000000001319.
    PubMed     Abstract available
    
    
    
92. MOENS A, Verstockt B, Machiels K, Bossuyt P, et al
    Clostridium difficile infection in inflammatory bowel disease: epidemiology over two decades.
    Eur J Gastroenterol Hepatol. 2019 Mar 4. doi: 10.1097/MEG.0000000000001394.
    PubMed     Abstract available
    
    
    January 2019
93. LIEFFERINCKX C, Minsart C, Cremer A, Amininejad L, et al
    Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance.
    Eur J Gastroenterol Hepatol. 2019 Jan 21. doi: 10.1097/MEG.0000000000001356.
    PubMed     Abstract available
    
    
    
94. ESSMANN J, Keil C, Unruh O, Otte A, et al
    Fecal calprotectin is significantly linked to azathioprine metabolite concentrations in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2019;31:99-108.
    PubMed     Abstract available
    
    
    December 2018
95. ORFANOUDAKI E, Gazouli M, Foteinogiannopoulou K, Theodoraki E, et al
    Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Eur J Gastroenterol Hepatol. 2018 Dec 12. doi: 10.1097/MEG.0000000000001332.
    PubMed     Abstract available
    
    
    
96. BHOYRUL B, Hilmy M, Lyon C
    Crohn's disease of the penis and scrotum: a prospective study.
    Eur J Gastroenterol Hepatol. 2018;30:1528-1529.
    PubMed    
    
    
    
97. VERDEJO C, Hervias D, Roncero O, Arias A, et al
    Fecal calprotectin is not superior to serum C-reactive protein or the Harvey-Bradshaw index in predicting postoperative endoscopic recurrence in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2018;30:1521-1527.
    PubMed     Abstract available
    
    
    October 2018
98. MOLENDIJK I, van der Meulen-de Jong AE, Verspaget HW, Veenendaal RA, et al
    Standardization of mesenchymal stromal cell therapy for perianal fistulizing Crohn's disease.
    Eur J Gastroenterol Hepatol. 2018;30:1148-1154.
    PubMed     Abstract available
    
    
    
99. AALTONEN G, Keranen I, Carpelan-Holmstrom M, Lepisto A, et al
    Risk factors for anastomotic recurrence after primary ileocaecal resection in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2018;30:1143-1147.
    PubMed     Abstract available
    
    
    
100. BOHN THOMSEN S, Kiszka-Kanowitz M, Theede K, Gluud LL, et al
     Optimized thiopurine therapy before withdrawal of anti-tumour necrosis factor-alpha in patients with Crohn's disease.
     Eur J Gastroenterol Hepatol. 2018;30:1155-1158.
     PubMed     Abstract available
     
     
     September 2018
101. JUNG ES, Petersen BS, Mayr G, Cheon JH, et al
     Compound heterozygous mutations in IL10RA combined with a complement factor properdin mutation in infantile-onset inflammatory bowel disease.
     Eur J Gastroenterol Hepatol. 2018 Sep 7. doi: 10.1097/MEG.0000000000001247.
     PubMed     Abstract available
     
     
     
102. MOSLI M, Alfaer S, Almalaki T, Albeshry A, et al
     Baseline risk assessment of patients with ulcerative colitis: does initial treatment selection influence outcomes?
     Eur J Gastroenterol Hepatol. 2018 Sep 7. doi: 10.1097/MEG.0000000000001249.
     PubMed     Abstract available
     
     
     
103. COENEN S, Schmickler MN, Staes D, Wieme F, et al
     Investing in workability of patients with inflammatory bowel disease: results of a pilot project Activ84worK (Activate for work).
     Eur J Gastroenterol Hepatol. 2018 Sep 5. doi: 10.1097/MEG.0000000000001257.
     PubMed     Abstract available
     
     
     
104. BRENNAN GT, Ha I, Hogan C, Nguyen E, et al
     Does preoperative enteral or parenteral nutrition reduce postoperative complications in Crohn's disease patients: a meta-analysis.
     Eur J Gastroenterol Hepatol. 2018;30:997-1002.
     PubMed     Abstract available
     
     
     August 2018
105. WALLDORF J, Twarz M, Schober C, Michl P, et al
     High frequency of secondary, but not primary ocular manifestations of inflammatory bowel disease in patients treated at a tertiary care center.
     Eur J Gastroenterol Hepatol. 2018 Aug 24. doi: 10.1097/MEG.0000000000001248.
     PubMed     Abstract available
     
     
     
106. ZAMMIT SC, Ellul P, Girardin G, Valpiani D, et al
     Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study.
     Eur J Gastroenterol Hepatol. 2018 Aug 21. doi: 10.1097/MEG.0000000000001238.
     PubMed     Abstract available
     
     
     
107. MITSELOS IV, Katsanos KH, Tatsioni A, Skamnelos A, et al
     Association of clinical and inflammatory markers with small bowel capsule endoscopy findings in Crohn's disease.
     Eur J Gastroenterol Hepatol. 2018;30:861-867.
     PubMed     Abstract available
     
     
     July 2018
108. SIMSEK M, Seinen ML, de Boer NKH
     Nodular regenerative hyperplasia in inflammatory bowel disease patients with allopurinol-thiopurine cotherapy.
     Eur J Gastroenterol Hepatol. 2018 Jul 30. doi: 10.1097/MEG.0000000000001218.
     PubMed    
     
     
     
109. DE CHAMBRUN GP, Nachury M, Funakoshi N, Gerard R, et al
     Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis.
     Eur J Gastroenterol Hepatol. 2018 Jul 26. doi: 10.1097/MEG.0000000000001223.
     PubMed     Abstract available
     
     
     
110. NAHON S, Ramtohul T, Paupard T, Belhassan M, et al
     Evolution in clinical presentation of inflammatory bowel disease over time at diagnosis: a multicenter cohort study.
     Eur J Gastroenterol Hepatol. 2018 Jul 12. doi: 10.1097/MEG.0000000000001201.
     PubMed     Abstract available
     
     
     
111. GUILCHER K, Fournier N, Schoepfer A, Schibli S, et al
     Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland.
     Eur J Gastroenterol Hepatol. 2018 Jul 5. doi: 10.1097/MEG.0000000000001197.
     PubMed     Abstract available
     
     
     
112. LO B, Julsgaard M, Vester-Andersen MK, Vind I, et al
     Disease activity, steroid use and extraintestinal manifestation are associated with increased disability in patients with inflammatory bowel disease using the inflammatory bowel disease disability index: a cross-sectional multicentre cohort study.
     Eur J Gastroenterol Hepatol. 2018 Jul 3. doi: 10.1097/MEG.0000000000001199.
     PubMed     Abstract available
     
     
     
113. KRIDIN K, Comaneshter D, Cohen AD
     Short article: Crohn's disease and pemphigus: is there an association?: a population-based study.
     Eur J Gastroenterol Hepatol. 2018;30:727-729.
     PubMed     Abstract available
     
     
     June 2018
114. REZAPOUR M, Galoosian A, Liu B, Bhuket T, et al
     Clostridium difficile co-infection in inflammatory bowel disease is associated with significantly increased in-hospital mortality.
     Eur J Gastroenterol Hepatol. 2018 Jun 11. doi: 10.1097/MEG.0000000000001185.
     PubMed     Abstract available
     
     
     
115. O'CONNELL J, Rowan C, Stack R, Harkin G, et al
     Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis.
     Eur J Gastroenterol Hepatol. 2018 Jun 6. doi: 10.1097/MEG.0000000000001177.
     PubMed     Abstract available
     
     
     May 2018
116. DERIKX LAAP, de Jong ME, Hoentjen F
     Recommendations on rectal surveillance for colorectal cancer after subtotal colectomy in patients with inflammatory bowel disease.
     Eur J Gastroenterol Hepatol. 2018 May 17. doi: 10.1097/MEG.0000000000001171.
     PubMed     Abstract available
     
     
     
117. SCHOEPFER A, Vavricka SR, Brungger B, Reich O, et al
     Systematic analysis of annual health resource utilization and costs in hospitalized patients with inflammatory bowel disease in Switzerland.
     Eur J Gastroenterol Hepatol. 2018 May 11. doi: 10.1097/MEG.0000000000001160.
     PubMed     Abstract available
     
     
     
118. EGEA-VALENZUELA J, Gonzalez Suarez B, Sierra Bernal C, Juanmartinena Fernandez JF, et al
     Development and validation of a scoring index to predict the presence of lesions in capsule endoscopy in patients with suspected Crohn's disease of the small bowel: a Spanish multicenter study.
     Eur J Gastroenterol Hepatol. 2018;30:499-505.
     PubMed     Abstract available
     
     
     
119. BOSSUYT P, Debeuckelaere C, Ferrante M, Vanbeckevoort D, et al
     The operative risk and natural history after the diagnosis of ileal penetrating Crohn's disease.
     Eur J Gastroenterol Hepatol. 2018;30:539-545.
     PubMed     Abstract available
     
     
     April 2018
120. CHAN W, Lynch N, Bampton P, Chang J, et al
     Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease.
     Eur J Gastroenterol Hepatol. 2018 Apr 30. doi: 10.1097/MEG.0000000000001150.
     PubMed     Abstract available
     
     
     
121. LAPUMNUAYPOL K, Kanjanahattakij N, Pisarcik D, Thongprayoon C, et al
     Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: a meta-analysis.
     Eur J Gastroenterol Hepatol. 2018 Apr 24. doi: 10.1097/MEG.0000000000001144.
     PubMed     Abstract available
     
     
     
122. MERAL M, Bengi G, Kayahan H, Akarsu M, et al
     Is ileocecal valve intubation essential for routine colonoscopic examination?
     Eur J Gastroenterol Hepatol. 2018;30:432-437.
     PubMed     Abstract available
     
     
     
123. PERNAT DROBEZ C, Repnik K, Gorenjak M, Ferkolj I, et al
     DNA polymorphisms predict time to progression from uncomplicated to complicated Crohn's disease.
     Eur J Gastroenterol Hepatol. 2018;30:447-455.
     PubMed     Abstract available
     
     
     
124. HOLKO P, Kawalec P, Stawowczyk E
     Prevalence and drug treatment practices of inflammatory bowel diseases in Poland in the years 2012-2014: an analysis of nationwide databases.
     Eur J Gastroenterol Hepatol. 2018;30:456-464.
     PubMed     Abstract available
     
     
     March 2018
125. HOEKSTRA J, van Roon AHC, Bekkering FC, van Tilburg AJP, et al
     Decision making and outcome of pregnancies in female patients with inflammatory bowel disease: findings from a community-based practice.
     Eur J Gastroenterol Hepatol. 2018 Mar 14. doi: 10.1097/MEG.0000000000001117.
     PubMed     Abstract available
     
     
     
126. BINKHORST L, Sobels A, Stuyt R, Westerman EM, et al
     Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
     Eur J Gastroenterol Hepatol. 2018 Mar 13. doi: 10.1097/MEG.0000000000001113.
     PubMed     Abstract available
     
     
     February 2018
127. LOBO JL, Garcia-Fuertes JA, Trujillo-Santos J, Merah A, et al
     Anticoagulant therapy for venous thromboembolism in patients with inflammatory bowel disease.
     Eur J Gastroenterol Hepatol. 2018 Feb 16. doi: 10.1097/MEG.0000000000001084.
     PubMed     Abstract available
     
     
     
128. NOBILE S, Grand RJ, Pappa HM
     Risk factors for low bone mineral density in pediatric inflammatory bowel disease: the positive role of physical activity.
     Eur J Gastroenterol Hepatol. 2018 Feb 12. doi: 10.1097/MEG.0000000000001076.
     PubMed     Abstract available
     
     
     
129. AKAR M, Aydin F, Yurci MA, Abay S, et al
     The possible relationship between Campylobacter spp./Arcobacter spp. and patients with ulcerative colitis.
     Eur J Gastroenterol Hepatol. 2018 Feb 9. doi: 10.1097/MEG.0000000000001095.
     PubMed     Abstract available
     
     
     
130. NULSEN B, Sands BE, Shah BJ, Ungaro RC, et al
     Practices, attitudes, and knowledge about Crohn's disease and smoking cessation among gastroenterologists.
     Eur J Gastroenterol Hepatol. 2018;30:155-160.
     PubMed     Abstract available
     
     
     
131. BROEKMAN MMTJ, Coenen MJH, Wanten GJ, van Marrewijk CJ, et al
     Patients' beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases.
     Eur J Gastroenterol Hepatol. 2018;30:167-173.
     PubMed     Abstract available
     
     
     January 2018
132. GODAT S, Fournier N, Safroneeva E, Juillerat P, et al
     Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort.
     Eur J Gastroenterol Hepatol. 2018 Jan 30. doi: 10.1097/MEG.0000000000001078.
     PubMed     Abstract available
     
     
     
133. HERZOG D, Fournier N, Buehr P, Rueger V, et al
     Age at disease onset of inflammatory bowel disease is associated with later extraintestinal manifestations and complications.
     Eur J Gastroenterol Hepatol. 2018 Jan 22. doi: 10.1097/MEG.0000000000001072.
     PubMed     Abstract available
     
     
     
134. ALLOCCA M, Gilardi D, Fiorino G, Furfaro F, et al
     Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men.
     Eur J Gastroenterol Hepatol. 2018 Jan 18. doi: 10.1097/MEG.0000000000001074.
     PubMed     Abstract available
     
     
     
135. VAN ERP SJH, van der Have M, Fidder HH, van der Heijde D, et al
     The effect of arthropathies on illness perceptions, coping strategies, outcomes, and their changes over time in patients with inflammatory bowel disease: a 12-month follow-up study.
     Eur J Gastroenterol Hepatol. 2018 Jan 12. doi: 10.1097/MEG.0000000000001066.
     PubMed     Abstract available
     
     
     
136. BLACKETT JW, Shamsunder M, Reilly NR, Green PHR, et al
     Characteristics and comorbidities of inpatients without celiac disease on a gluten-free diet.
     Eur J Gastroenterol Hepatol. 2018 Jan 8. doi: 10.1097/MEG.0000000000001071.
     PubMed     Abstract available
     
     
     
137. KRAJCOVICOVA A, Kuzma M, Hlavaty T, Hans D, et al
     Decrease of trabecular bone score reflects severity of Crohn's disease: results of a case-control study.
     Eur J Gastroenterol Hepatol. 2018;30:101-106.
     PubMed     Abstract available
     
     
     December 2017
138. WALLDORF J, Brunne S, Gittinger FS, Michl P, et al
     Family planning in inflammatory bowel disease: childlessness and disease-related concerns among female patients.
     Eur J Gastroenterol Hepatol. 2017 Dec 5. doi: 10.1097/MEG.0000000000001037.
     PubMed     Abstract available
     
     
     November 2017
139. HOLKO P, Kawalec P, Mossakowska M
     Quality of life related to oral, subcutaneous, and intravenous biologic treatment of inflammatory bowel disease: a time trade-off study.
     Eur J Gastroenterol Hepatol. 2017 Nov 29. doi: 10.1097/MEG.0000000000001031.
     PubMed     Abstract available
     
     
     
140. WILLEMZE RA, Bakker T, Pippias M, Ponsioen CY, et al
     beta-Blocker use is associated with a higher relapse risk of inflammatory bowel disease: a Dutch retrospective case-control study.
     Eur J Gastroenterol Hepatol. 2017 Nov 3. doi: 10.1097/MEG.0000000000001016.
     PubMed     Abstract available
     
     
     October 2017
141. SKUJA V, Derovs A, Pekarska K, Rudzite D, et al
     Gut colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae may increase disease activity in biologic-naive outpatients with ulcerative colitis: an interim analysis.
     Eur J Gastroenterol Hepatol. 2017 Oct 25. doi: 10.1097/MEG.0000000000000989.
     PubMed     Abstract available
     
     
     September 2017
142. BATTAT R, Kopylov U, Byer J, Sewitch MJ, et al
     Vitamin B12 deficiency in inflammatory bowel disease: a prospective observational pilot study.
     Eur J Gastroenterol Hepatol. 2017 Sep 25. doi: 10.1097/MEG.0000000000000970.
     PubMed     Abstract available
     
     
     
143. ARGUELLES-ARIAS F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, et al
     Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
     Eur J Gastroenterol Hepatol. 2017 Sep 8. doi: 10.1097/MEG.0000000000000953.
     PubMed     Abstract available
     
     
     
144. TIMMER A, Stark R, Peplies J, Classen M, et al
     Current health status and medical therapy of patients with pediatric-onset inflammatory bowel disease: a survey-based analysis on 1280 patients aged 10-25 years focusing on differences by age of onset.
     Eur J Gastroenterol Hepatol. 2017 Sep 4. doi: 10.1097/MEG.0000000000000956.
     PubMed     Abstract available
     
     
     August 2017
145. COUCOUTSI C, Emmanouil G, Goulielmos G, Sfakianaki O, et al
     Prevalence of thiopurine S-methyltransferase gene polymorphisms in patients with inflammatory bowel disease from the island of Crete, Greece.
     Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000947.
     PubMed     Abstract available
     
     
     June 2017
146. HOEKMAN DR, Zeevenhooven J, D'Haens GR, Benninga MA, et al
     The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
     Eur J Gastroenterol Hepatol. 2017 Jun 21. doi: 10.1097/MEG.0000000000000921.
     PubMed     Abstract available
     
     
     
147. CARDILE S, Candusso M, Papadatou B, Bracci F, et al
     Lack of efficacy of infliximab in the treatment of primary sclerosing cholangitis in inflammatory bowel diseases in childhood.
     Eur J Gastroenterol Hepatol. 2017;29:736.
     PubMed    
     
     
     May 2017
148. ORTIZO R, Lee SY, Nguyen ET, Jamal MM, et al
     Exposure to oral contraceptives increases the risk for development of inflammatory bowel disease: a meta-analysis of case-controlled and cohort studies.
     Eur J Gastroenterol Hepatol. 2017 May 24. doi: 10.1097/MEG.0000000000000915.
     PubMed     Abstract available
     
     
     
149. RINAWI F, Assa A, Eliakim R, Mozer Glassberg Y, et al
     Predictors of pouchitis after ileal pouch-anal anastomosis in pediatric-onset ulcerative colitis.
     Eur J Gastroenterol Hepatol. 2017 May 24. doi: 10.1097/MEG.0000000000000914.
     PubMed     Abstract available
     
     
     
150. BAHLER C, Schoepfer AM, Vavricka SR, Brungger B, et al
     Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland.
     Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000891.
     PubMed     Abstract available
     
     
     
151. WARDLE RA, Wardle AJ, Charadva C, Ghosh S, et al
     Literature review: impacts of socioeconomic status on the risk of inflammatory bowel disease and its outcomes.
     Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000899.
     PubMed     Abstract available
     
     
     
152. HERZOG D, Fournier N, Buehr P, Rueger V, et al
     Prevalence of intestinal complications in inflammatory bowel disease: a comparison between paediatric-onset and adult-onset patients.
     Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000896.
     PubMed     Abstract available
     
     
     
153. SLONIM-NEVO V, Sarid O, Friger M, Schwartz D, et al
     Effect of threatening life experiences and adverse family relations in ulcerative colitis: analysis using structural equation modeling and comparison with Crohn's disease.
     Eur J Gastroenterol Hepatol. 2017;29:577-586.
     PubMed     Abstract available
     
     
     
154. CHEN D, Luo S, Ben Q, Lu L, et al
     Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China.
     Eur J Gastroenterol Hepatol. 2017;29:509-515.
     PubMed     Abstract available
     
     
     
155. GOTTGENS KW, Jeuring SF, Sturkenboom R, Romberg-Camps MJ, et al
     Time trends in the epidemiology and outcome of perianal fistulizing Crohn's disease in a population-based cohort.
     Eur J Gastroenterol Hepatol. 2017;29:595-601.
     PubMed     Abstract available
     
     
     
156. WICKBOM A, Nyhlin N, Montgomery SM, Bohr J, et al
     Family history, comorbidity, smoking and other risk factors in microscopic colitis: a case-control study.
     Eur J Gastroenterol Hepatol. 2017;29:587-594.
     PubMed     Abstract available
     
     
     April 2017
157. DRAGASEVIC S, Stankovic B, Milosavljevic T, Sokic-Milutinovic A, et al
     Genetic and environmental factors significant for the presentation and development of inflammatory bowel disease.
     Eur J Gastroenterol Hepatol. 2017 Apr 27. doi: 10.1097/MEG.0000000000000877.
     PubMed     Abstract available
     
     
     March 2017
158. VAN DEEN WK, Spiro A, Burak Ozbay A, Skup M, et al
     The impact of value-based healthcare for inflammatory bowel diseases on healthcare utilization: a pilot study.
     Eur J Gastroenterol Hepatol. 2017;29:331-337.
     PubMed     Abstract available
     
     
     February 2017
159. YERUSHALMY-FELER A, Ron Y, Barnea E, Nachum A, et al
     Adolescent transition clinic in inflammatory bowel disease: quantitative assessment of self-efficacy skills.
     Eur J Gastroenterol Hepatol. 2017 Feb 22. doi: 10.1097/MEG.0000000000000864.
     PubMed     Abstract available
     
     
     
160. TRIANTAFYLLOU K, Gkolfakis P, Viazis N, Tsibouris P, et al
     A 13-year time trend analysis of 3724 small bowel video capsule endoscopies and a forecast model during the financial crisis in Greece.
     Eur J Gastroenterol Hepatol. 2017;29:185-191.
     PubMed     Abstract available
     
     
     
161. DURICOVA D, Fumery M, Annese V, Lakatos PL, et al
     The natural history of Crohn's disease in children: a review of population-based studies.
     Eur J Gastroenterol Hepatol. 2017;29:125-134.
     PubMed     Abstract available
     
     
     January 2017
162. CHEN D, Luo S, Ben Q, Lu L, et al
     Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China.
     Eur J Gastroenterol Hepatol. 2017 Jan 21. doi: 10.1097/MEG.0000000000000838.
     PubMed     Abstract available
     
     
     
163. COENEN S, Weyts E, Vermeire S, Ferrante M, et al
     Effects of introduction of an inflammatory bowel disease nurse position on the quality of delivered care.
     Eur J Gastroenterol Hepatol. 2017 Jan 21. doi: 10.1097/MEG.0000000000000839.
     PubMed     Abstract available
     
     
     
164. SLONIM-NEVO V, Sarid O, Friger M, Schwartz D, et al
     Effect of threatening life experiences and adverse family relations in ulcerative colitis: analysis using structural equation modeling and comparison with Crohn's disease.
     Eur J Gastroenterol Hepatol. 2017 Jan 4. doi: 10.1097/MEG.0000000000000826.
     PubMed     Abstract available
     
     
     December 2016
165. VAN ERP SJ, Verheul MK, Levarht EW, van der Reijden JJ, et al
     Absence of serological rheumatoid arthritis biomarkers in inflammatory bowel disease patients with arthropathies.
     Eur J Gastroenterol Hepatol. 2016.
     PubMed     Abstract available
     
     
     
166. ROSSI RE, Whyand T, Murray CD, Hamilton MI, et al
     The role of dietary supplements in inflammatory bowel disease: a systematic review.
     Eur J Gastroenterol Hepatol. 2016;28:1357-1364.
     PubMed     Abstract available
     
     
     November 2016
167. VAN GENNEP S, Sahami S, Buskens CJ, van den Brink GR, et al
     Comparison of health-related quality of life and disability in ulcerative colitis patients following restorative proctocolectomy with ileal pouch-anal anastomosis versus anti-tumor necrosis factor therapy.
     Eur J Gastroenterol Hepatol. 2016.
     PubMed     Abstract available
     
     
     
168. ZEITZ J, Bissig M, Barthel C, Biedermann L, et al
     Patients' views on fecal microbiota transplantation: an acceptable therapeutic option in inflammatory bowel disease?
     Eur J Gastroenterol Hepatol. 2016.
     PubMed     Abstract available
     
     
     
169. FALT P, Smajstrla V, Fojtik P, Hill M, et al
     Carbon dioxide insufflation during colonoscopy in inflammatory bowel disease patients: a double-blind, randomized, single-center trial.
     Eur J Gastroenterol Hepatol. 2016.
     PubMed     Abstract available
     
     
     October 2016
170. GOYAL H, Singla U, Gupta U, May E, et al
     Role of cannabis in digestive disorders.
     Eur J Gastroenterol Hepatol. 2016.
     PubMed     Abstract available
     
     
     
171. TAKS M, Pijls PA, Derijks LJ, Ten Broeke R, et al
     The effect of implementation of a treatment algorithm for infliximab on remission rates and drug costs in inflammatory bowel disease patients.
     Eur J Gastroenterol Hepatol. 2016.
     PubMed     Abstract available
     
     
     
172. JOHNSEN KM, Goll R, Hansen V, Olsen T, et al
     Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm.
     Eur J Gastroenterol Hepatol. 2016.
     PubMed     Abstract available
     
     
     September 2016
173. FRAGA M, Fournier N, Safroneeva E, Pittet V, et al
     Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up.
     Eur J Gastroenterol Hepatol. 2016.
     PubMed     Abstract available
     
     
     April 2016
174. LEE YJ, Hwang EH, Park JH, Shin JH, et al
     NUDT15 variant is the most common variant associated with thiopurine-induced early leukopenia and alopecia in Korean pediatric patients with Crohn's disease.
     Eur J Gastroenterol Hepatol. 2016;28:475-8.
     PubMed     Abstract available
     
     
     March 2016
175. MADIRRALA V, Rooney P, Heath RM, Campbell F, et al
     Short article: Successful faecal coliform sensitivity-based oral ertapenem therapy for chronic antibiotic-refractory pouchitis: a case series.
     Eur J Gastroenterol Hepatol. 2016;28:277-80.
     PubMed     Abstract available
     
     
     
176. BOND A, Asher R, Jackson R, Sager K, et al
     Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels.
     Eur J Gastroenterol Hepatol. 2016;28:271-6.
     PubMed     Abstract available
     
     
     February 2016
177. KUIN S, Stolte SB, van den Brink GR, Ponsioen CY, et al
     Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.
     Eur J Gastroenterol Hepatol. 2016;28:222-5.
     PubMed     Abstract available
     
     
     January 2016
178. WAHID AM, Devarajan K, Ross A, Zilbauer M, et al
     Paediatric gastrointestinal endoscopy: a qualitative study.
     Eur J Gastroenterol Hepatol. 2016;28:25-9.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: